Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients

Carlayne E. Jackson; Gary Gronseth; Jeffrey Rosenfeld; Richard J. Barohn; Richard Dubinsky; C. Blake Simpson; April Mcvey; Pamela P. Kittrell; Ruth King; Laura Herbelin; Robert Griggs; Rabi Tawil; Carlayne Jackson; John T. Kissel; Shree Pandya; Karen Downing; Michael Rose; Michael McDermott

doi:10.1002/mus.21213

Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients

Carlayne E. Jackson, Gary Gronseth, Jeffrey Rosenfeld, Richard J. Barohn, Richard Dubinsky, C. Blake Simpson, April Mcvey, Pamela P. Kittrell, Ruth King, Laura Herbelin, Robert Griggs, Rabi Tawil, Carlayne Jackson, John T. Kissel, Shree Pandya, Karen Downing, Michael Rose, Michael McDermott

Research output: Contribution to journal › Article › peer-review

121 Scopus citations

Abstract

Twenty ALS patients with sialorrhea refractory to medical therapy were enrolled in this double-blind, randomized study to receive either 2,500 U of botulinum toxin type B (BTxb) or placebo into the bilateral parotid and submandibular glands using electromyographic guidance. Patients who received BTxb reported a global impression of improvement of 82% at 2 weeks compared to 38% of those who received placebo (P < 0.05). This significant effect was sustained at 4 weeks. At 12 weeks, 50% of patients who received BTxb continued to report improvement compared to 14% of those who received placebo. There were no significant adverse events, including dysphagia, in the BTxb group, and there was no significant increase in the rate of decline of vital capacity.

Original language	English (US)
Pages (from-to)	137-143
Number of pages	7
Journal	Muscle and Nerve
Volume	39
Issue number	2
DOIs	https://doi.org/10.1002/mus.21213
State	Published - Feb 2009

Keywords

Amyotrophic lateral sclerosis
Botulinum toxin
Drooling
Quality of life
Sialorrhea

ASJC Scopus subject areas

Clinical Neurology
Physiology (medical)
Cellular and Molecular Neuroscience
Physiology

Access to Document

10.1002/mus.21213

Cite this

Jackson, C. E., Gronseth, G., Rosenfeld, J., Barohn, R. J., Dubinsky, R., Simpson, C. B., Mcvey, A., Kittrell, P. P., King, R., Herbelin, L., Griggs, R., Tawil, R., Jackson, C., Kissel, J. T., Pandya, S., Downing, K., Rose, M., & McDermott, M. (2009). Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle and Nerve, 39(2), 137-143. https://doi.org/10.1002/mus.21213

Jackson, CE, Gronseth, G, Rosenfeld, J, Barohn, RJ, Dubinsky, R, Simpson, CB, Mcvey, A, Kittrell, PP, King, R, Herbelin, L, Griggs, R, Tawil, R, Jackson, C, Kissel, JT, Pandya, S, Downing, K, Rose, M & McDermott, M 2009, 'Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients', Muscle and Nerve, vol. 39, no. 2, pp. 137-143. https://doi.org/10.1002/mus.21213

@article{a65763b32f1e4109be599c1df332acf2,

title = "Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients",

abstract = "Twenty ALS patients with sialorrhea refractory to medical therapy were enrolled in this double-blind, randomized study to receive either 2,500 U of botulinum toxin type B (BTxb) or placebo into the bilateral parotid and submandibular glands using electromyographic guidance. Patients who received BTxb reported a global impression of improvement of 82% at 2 weeks compared to 38% of those who received placebo (P < 0.05). This significant effect was sustained at 4 weeks. At 12 weeks, 50% of patients who received BTxb continued to report improvement compared to 14% of those who received placebo. There were no significant adverse events, including dysphagia, in the BTxb group, and there was no significant increase in the rate of decline of vital capacity.",

keywords = "Amyotrophic lateral sclerosis, Botulinum toxin, Drooling, Quality of life, Sialorrhea",

author = "Jackson, {Carlayne E.} and Gary Gronseth and Jeffrey Rosenfeld and Barohn, {Richard J.} and Richard Dubinsky and Simpson, {C. Blake} and April Mcvey and Kittrell, {Pamela P.} and Ruth King and Laura Herbelin and Robert Griggs and Rabi Tawil and Carlayne Jackson and Kissel, {John T.} and Shree Pandya and Karen Downing and Michael Rose and Michael McDermott",

year = "2009",

month = feb,

doi = "10.1002/mus.21213",

language = "English (US)",

volume = "39",

pages = "137--143",

journal = "Muscle and Nerve",

issn = "0148-639X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients

AU - Jackson, Carlayne E.

AU - Gronseth, Gary

AU - Rosenfeld, Jeffrey

AU - Barohn, Richard J.

AU - Dubinsky, Richard

AU - Simpson, C. Blake

AU - Mcvey, April

AU - Kittrell, Pamela P.

AU - King, Ruth

AU - Herbelin, Laura

AU - Griggs, Robert

AU - Tawil, Rabi

AU - Jackson, Carlayne

AU - Kissel, John T.

AU - Pandya, Shree

AU - Downing, Karen

AU - Rose, Michael

AU - McDermott, Michael

PY - 2009/2

Y1 - 2009/2

N2 - Twenty ALS patients with sialorrhea refractory to medical therapy were enrolled in this double-blind, randomized study to receive either 2,500 U of botulinum toxin type B (BTxb) or placebo into the bilateral parotid and submandibular glands using electromyographic guidance. Patients who received BTxb reported a global impression of improvement of 82% at 2 weeks compared to 38% of those who received placebo (P < 0.05). This significant effect was sustained at 4 weeks. At 12 weeks, 50% of patients who received BTxb continued to report improvement compared to 14% of those who received placebo. There were no significant adverse events, including dysphagia, in the BTxb group, and there was no significant increase in the rate of decline of vital capacity.

AB - Twenty ALS patients with sialorrhea refractory to medical therapy were enrolled in this double-blind, randomized study to receive either 2,500 U of botulinum toxin type B (BTxb) or placebo into the bilateral parotid and submandibular glands using electromyographic guidance. Patients who received BTxb reported a global impression of improvement of 82% at 2 weeks compared to 38% of those who received placebo (P < 0.05). This significant effect was sustained at 4 weeks. At 12 weeks, 50% of patients who received BTxb continued to report improvement compared to 14% of those who received placebo. There were no significant adverse events, including dysphagia, in the BTxb group, and there was no significant increase in the rate of decline of vital capacity.

KW - Amyotrophic lateral sclerosis

KW - Botulinum toxin

KW - Drooling

KW - Quality of life

KW - Sialorrhea

UR - http://www.scopus.com/inward/record.url?scp=60549090832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549090832&partnerID=8YFLogxK

U2 - 10.1002/mus.21213

DO - 10.1002/mus.21213

M3 - Article

C2 - 19145653

AN - SCOPUS:60549090832

SN - 0148-639X

VL - 39

SP - 137

EP - 143

JO - Muscle and Nerve

JF - Muscle and Nerve

IS - 2

ER -

Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this